CRISPR Therapeutics reported fourth-quarter 2020 loss per share of $1.50, wider than the Zacks Consensus Estimate of a loss of $1.23. However, the ...
Source link
CRISPR Therapeutics reported fourth-quarter 2020 loss per share of $1.50, wider than the Zacks Consensus Estimate of a loss of $1.23. However, the ...
Source link